

Hypothalamic Regulation of Glucose-Stimulated Insulin Secretion

Owen Chan and Robert S. Sherwin

Circulating glucose levels serve as the principal regulator of the rate of insulin secretion from the pancreatic β -cell, which, in turn, is the body's principal mechanism preventing excessive elevation in circulating glucose. The control center for this critical negative feedback loop is generally thought to reside solely within the province of the β -cell. However, in the February issue of *Diabetes*, Osundiji et al. (1) provide evidence that there may be another player involved, namely, the hypothalamus. They observed that raising glucose levels locally or pharmacologically blocking glucose entry into cells close to the third ventricle of the rat altered the acute insulin secretory response to intravenous glucose, presumably by the extensive neural connections that exist between the hypothalamus and islet. As pointed out by the authors, it is now well recognized that a subgroup of hypothalamic neurons, and neurons elsewhere in the brain, have the capacity to sense glucose and influence the secretion of anti-insulin hormones and hepatic glucose production (2–6). Yet, the idea that the glucose-sensing capacity of these neurons may also influence the function of the β -cell has not been appreciated, and if shown to be true under more physiological conditions, could have important therapeutic implications.

It is commonly believed that the K_{ATP} -dependent model of glucose-stimulated secretion coupling is the primary means used by the β -cell to activate insulin secretion (7–10). In this model, glucose enters the β -cell, is phosphorylated by glucokinase to glucose-6-phosphate, and then enters the glycolytic and oxidative phosphorylation pathways to be metabolized. Through this, ATP is generated, causing ATP-sensitive potassium channel closure, plasma membrane depolarization, and activation of voltage-gated calcium channels, which ultimately cause exocytosis of insulin-containing granules. Although the components of this mechanism are expressed in the β -cell and appear adequate to explain most insulin responses to glucose, there is a growing body of data that cannot be solely explained by this K_{ATP} -dependent mechanism of glucose-stimulated insulin secretion (GSIS). As a result, signals other than the ATP/ADP ratio have been postulated in recent years (11–16). These K_{ATP} -independent mechanisms have mainly focused on the mitochondria and generation of second messengers

other than ATP. In these models, it is postulated that conversion of pyruvate to oxaloacetate by pyruvate carboxylase leads to generation of a number of intermediary metabolites that are capable of acting as signals to stimulate insulin release (17,18). Some of these messengers, including NADPH (19–21), malonyl-CoA/long-chain CoA (22,23), short-chain CoA (24), glutamate (25), α -ketoglutarate (26), and GTP (27), are thought to act either directly or indirectly to alter the influx of calcium into the β -cell, ultimately affecting insulin secretory kinetics.

While studies examining GSIS have focused on factors that directly affect the β -cell, little attention has been given to the potential role of the brain in this regard. The brain and islet are tightly linked functionally through neural-entero-islet, brain-islet, and islet-brain axes. Thus, secretion of insulin and other islet hormones are clearly influenced by the hypothalamus and other brain areas, and conversely, insulin action in the hypothalamus influences both energy balance and glucose metabolism. The article in the February issue of *Diabetes* (1) presents some novel observations suggesting that hypothalamic glucose sensing may also provide an additional input to β -cells that modulates the first-phase insulin response to a glucose stimulus. In particular, data are presented suggesting that conversion of glucose to glucose-6-phosphate by glucokinase in the hypothalamus may serve to regulate the first phase of insulin secretion in response to glucose. Thirty minutes prior to giving an intravenous glucose tolerance test, the authors administered either glucose to activate glucokinase or one of two pharmacological inhibitors of glucokinase (glucosamine or mannoheptulose) into the third ventricle. When glucose was administered, a greater insulin secretory response occurred, along with a more rapid decline in plasma glucose levels. Conversely, when either of the nonspecific glucokinase inhibitors was administered, the acute insulin response to intravenous glucose was diminished and glucose excursions were slightly greater. The effect was more pronounced with glucosamine. This may be because glucosamine cannot only inhibit glucokinase, but it may also enter cells via glucose transporters, thereby redirecting intermediary metabolites of glycolysis into the hexosamine biosynthetic pathway. It should be noted that the study design employed a time-sequenced exposure of glucose or glucokinase inhibitors to the brain much before peripheral changes in glucose were induced in the experiments. This may have magnified the impact of the hypothalamus relative to what occurs in the physiological setting. Undoubtedly, more specific reductions in glucokinase gene expression within the hypothalamus will be required before the physiological importance of these specific observations can be determined.

Nonetheless, findings implicating the hypothalamus in GSIS are consistent with recent reports examining the role of insulin and glucose transport in the brain. We have reported that chronic knockdown of insulin receptors in

From the Department of Internal Medicine, Section of Endocrinology, Yale School of Medicine, New Haven, Connecticut.

Corresponding author: Robert S. Sherwin, robert.sherwin@yale.edu.

DOI: 10.2337/db11-1846

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

See accompanying original article published in *Diabetes* 2012;61:321–328

the ventromedial hypothalamus reduces insulin secretory responses to a standardized hyperglycemic stimulus (28). In addition, data from the laboratories of Simon Fisher and Domenico Accili indicate that deletion of the insulin-responsive glucose transporter, GLUT4, in the brain leads to impairments in glucose sensing and glucose tolerance in mice (29,30). Together, these data support the role of an insulin-responsive glucose-sensing mechanism within the hypothalamus that regulates islet hormone secretion to maintain glucose homeostasis. One can postulate that following meal ingestion, the rapid rise in peripheral glucose levels acts to initiate the insulin response. Subsequent rises in insulin and glucose may work together to stimulate an increase in glucose uptake by hypothalamic glucose-responsive neurons that further augment insulin secretion and increase glucose handling. Under conditions where central insulin resistance develops, it is intriguing to speculate that a reduction in the capacity to take up glucose in the hypothalamus may contribute to a diminution of the GSIS response.

It is becoming increasingly evident that GSIS likely involves several signaling events that converge to activate exocytosis of insulin-containing granules from the β -cell. The study by Osundiji et al. (1) adds yet another dimension to this already complicated story by providing some of the first evidence that a central nervous system glucose-responsive input might be involved in regulating the early insulin secretory response to a glucose stimulus. On the other hand, it should be emphasized that the observed effects were modest and that peripheral signals are still likely to play the dominant role in initiating insulin release. The brain, which is likely delayed in seeing changes in glucose concentrations, most likely provides a later signal to modulate the magnitude of the response. It will be interesting to see whether this response is due solely to a change in glucose levels or whether it is in response to a rapid rise in insulin. As the authors indicated, this may have important implications for the development of therapeutic strategies in the future.

ACKNOWLEDGMENTS

No potential conflicts of interest relevant to this article were reported.

REFERENCES

- Osundiji MA, Lam DD, Shaw J, et al. Brain glucose sensors play a significant role in the regulation of pancreatic glucose-stimulated insulin secretion. *Diabetes* 2012;61:321–328
- Borg MA, Sherwin RS, Borg WP, Tamborlane WV, Shulman GI. Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. *J Clin Invest* 1997;99:361–365
- Borg WP, Sherwin RS, Doring MJ, Borg MA, Shulman GI. Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release. *Diabetes* 1995;44:180–184
- Lam CK, Chari M, Rutter GA, Lam TK. Hypothalamic nutrient sensing activates a forebrain-hindbrain neuronal circuit to regulate glucose production in vivo. *Diabetes* 2011;60:107–113
- Levin BE, Dunn-Meynell AA, Routh VH. CNS sensing and regulation of peripheral glucose levels. *Int Rev Neurobiol* 2002;51:219–258
- Sanders NM, Taborsky GJ Jr, Wilkinson CW, Daumen W, Flegel DP. Antecedent hindbrain glucoprivation does not impair the counterregulatory response to hypoglycemia. *Diabetes* 2007;56:217–223
- Meglasson MD, Matschinsky FM. Pancreatic islet glucose metabolism and regulation of insulin secretion. *Diabetes Metab Rev* 1986;2:163–214
- Newgard CB, McGarry JD. Metabolic coupling factors in pancreatic beta-cell signal transduction. *Annu Rev Biochem* 1995;64:689–719
- Chan CB, MacPhail RM. KATP channel-dependent and -independent pathways of insulin secretion in isolated islets from fa/fa Zucker rats. *Biochem Cell Biol* 1996;74:403–410
- Miki T, Nagashima K, Tashiro F, et al. Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. *Proc Natl Acad Sci U S A* 1998;95:10402–10406
- Gembal M, Gilon P, Henquin JC. Evidence that glucose can control insulin release independently from its action on ATP-sensitive K^+ channels in mouse B cells. *J Clin Invest* 1992;89:1288–1295
- Komatsu M, Yajima H, Yamada S, et al. Augmentation of Ca^{2+} -stimulated insulin release by glucose and long-chain fatty acids in rat pancreatic islets: free fatty acids mimic ATP-sensitive K^+ channel-independent insulinotropic action of glucose. *Diabetes* 1999;48:1543–1549
- Nenquin M, Szollosi A, Aguilar-Bryan L, Bryan J, Henquin JC. Both triggering and amplifying pathways contribute to fuel-induced insulin secretion in the absence of sulfonylurea receptor-1 in pancreatic beta-cells. *J Biol Chem* 2004;279:32316–32324
- Remedi MS, Rocheleau JV, Tong A, et al. Hyperinsulinism in mice with heterozygous loss of $K(ATP)$ channels. *Diabetologia* 2006;49:2368–2378
- Shiota C, Larsson O, Shelton KD, et al. Sulfonylurea receptor type 1 knockout mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. *J Biol Chem* 2002;277:37176–37183
- Straub SG, Sharp GW. Glucose-stimulated signaling pathways in biphasic insulin secretion. *Diabetes Metab Res Rev* 2002;18:451–463
- Lu D, Mulder H, Zhao P, et al. ^{13}C NMR isotopomer analysis reveals a connection between pyruvate cycling and glucose-stimulated insulin secretion (GSIS). *Proc Natl Acad Sci U S A* 2002;99:2708–2713
- MacDonald MJ. Feasibility of a mitochondrial pyruvate malate shuttle in pancreatic islets. Further implication of cytosolic NADPH in insulin secretion. *J Biol Chem* 1995;270:20051–20058
- Ivarsson R, Quintens R, Dejonghe S, et al. Redox control of exocytosis: regulatory role of NADPH, thioredoxin, and glutaredoxin. *Diabetes* 2005;54:2132–2142
- MacDonald MJ, Fahien LA, Brown LJ, Hasan NM, Buss JD, Kendrick MA. Perspective: emerging evidence for signaling roles of mitochondrial anaplerotic products in insulin secretion. *Am J Physiol Endocrinol Metab* 2005;288:E1–E15
- Ronnebaum SM, Ilkayeva O, Burgess SC, et al. A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. *J Biol Chem* 2006;281:30593–30602
- Corkey BE, Glennon MC, Chen KS, Deeney JT, Matschinsky FM, Prentki M. A role for malonyl-CoA in glucose-stimulated insulin secretion from clonal pancreatic beta-cells. *J Biol Chem* 1989;264:21608–21612
- Prentki M, Vischer S, Glennon MC, Regazzi R, Deeney JT, Corkey BE. Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. *J Biol Chem* 1992;267:5802–5810
- MacDonald MJ, Longacre MJ, Stoker SW, Brown LJ, Hasan NM, Kendrick MA. Acetoacetate and beta-hydroxybutyrate in combination with other metabolites release insulin from INS-1 cells and provide clues about pathways in insulin secretion. *Am J Physiol Cell Physiol* 2008;294:C442–C450
- Maechler P, Wollheim CB. Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. *Nature* 1999;402:685–689
- Rabaglia ME, Gray-Keller MP, Frey BL, Shortreed MR, Smith LM, Attie AD. Alpha-ketoisocaproate-induced hypersecretion of insulin by islets from diabetes-susceptible mice. *Am J Physiol Endocrinol Metab* 2005;289:E218–E224
- Kibbey RG, Pongratz RL, Romanelli AJ, Wollheim CB, Cline GW, Shulman GI. Mitochondrial GTP regulates glucose-stimulated insulin secretion. *Cell Metab* 2007;5:253–264
- Paranjape SA, Chan O, Zhu W, et al. Chronic reduction of insulin receptors in the ventromedial hypothalamus produces glucose intolerance and islet dysfunction in the absence of weight gain. *Am J Physiol Endocrinol Metab* 2011;301:E978–E983
- Reno C, Puente E, Daphna-Iken D, Kahn BB, Fisher SJ. Brain specific glucose transporter 4 knockout mice display decreased brain glucose uptake and hepatic insulin resistance (Abstract). *Diabetes* 2010;59(Suppl. 1):A81
- Lin HV, Ren H, Samuel VT, et al. Diabetes in mice with selective impairment of insulin action in *Glut4*-expressing tissues. *Diabetes* 2011;60:700–709